Related Experiment Video

Updated: Apr 7, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.8K

Treatment with propranolol for infantile hemangiomas: A case series of 106 infants

Shang-Bin Li1, Guang-Qi Xu1, Feng Gao1

  • 1Department of Aesthetic, Plastic and Burn Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.

Experimental and Therapeutic Medicine
|July 15, 2015
PubMed

Insights

Propranolol effectively treats infantile hemangiomas (IHs) in children, showing rapid therapeutic benefits with minimal side effects. This study confirms its clinical utility in managing IHs.

Area of Science:

  • Pediatric Dermatology
  • Clinical Pharmacology

Background:

  • Infantile hemangiomas (IHs) are common vascular tumors in infants.
  • Effective and safe treatment options for IHs are crucial for optimal outcomes.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of propranolol for treating infantile hemangiomas in pediatric patients.
  • To assess the side effects and therapeutic response to propranolol in children with IHs.

Main Methods:

  • Retrospective chart review of 106 children with IHs treated between 2009 and 2013.
  • Propranolol administered orally at a dosage of 1.0-1.5 mg/kg/day in divided doses.
  • Evaluation of demographic data, clinical features, treatment outcomes, and adverse events.

Main Results:

  • All 106 patients demonstrated a positive response to propranolol treatment.
  • Common side effects included diarrhea (10), hypotension (7), nightmares (2), agitation (1), and cold extremities (1).
  • No long-term adverse effects were reported in any patient.

Conclusions:

  • Oral propranolol at 1.0-1.5 mg/kg/day provides a rapid therapeutic effect for infantile hemangiomas.
  • The treatment is associated with few complications, making it a safe option for pediatric patients.
  • Propranolol is a beneficial treatment for IHs, with a favorable safety profile in children.

Keywords:
hemangiomasinfantspropranololside effects

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.5K
Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles03:06

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

1.2K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
817
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
469